KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Retained Earnings: 2020-2025

Historic Retained Earnings for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to -$2.0 billion.

  • Recursion Pharmaceuticals' Retained Earnings fell 53.85% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 53.85%. This contributed to the annual value of -$1.4 billion for FY2024, which is 47.92% down from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Retained Earnings is -$2.0 billion, which was down 10.77% from -$1.8 billion recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Retained Earnings high stood at -$244.3 million for Q1 2021, and its period low was -$2.0 billion during Q3 2025.
  • Over the past 3 years, Recursion Pharmaceuticals' median Retained Earnings value was -$1.2 billion (recorded in 2024), while the average stood at -$1.3 billion.
  • Data for Recursion Pharmaceuticals' Retained Earnings shows a maximum YoY crashed of 87.30% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Retained Earnings stood at -$400.1 million in 2021, then crashed by 59.86% to -$639.6 million in 2022, then crashed by 51.30% to -$967.6 million in 2023, then crashed by 47.92% to -$1.4 billion in 2024, then tumbled by 53.85% to -$2.0 billion in 2025.
  • Its last three reported values are -$2.0 billion in Q3 2025, -$1.8 billion for Q2 2025, and -$1.6 billion during Q1 2025.